Citable filing context
CTVA's research view summarizes recent SEC filing context, starting with other from Aug 14, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 14, 2026 | other | Corteva subsidiary Vylor, Inc. filed a Form 10 registration statement for its planned spin-off as an independent company. |
| Aug 6, 2026 | debt_offering | Vylor entered into $7.25 billion in new credit facilities to support its planned separation from Corteva. |
| Jul 30, 2026 | earnings | Corteva reported Q2 2026 financial results and raised its full-year 2026 Operating EBITDA guidance to $4.1-$4.3 billion. |
| Aug 6, 2026 | Guidance: debt_to_ebitda_leverage_ratio | not reported to 2.00 |
| Aug 6, 2026 | Guidance: debt_to_ebitda_leverage_ratio | 0.80 to 1.10 |
| Jul 30, 2026 | Guidance: operating_ebitda | 4100.00 to 4300.00 |
| Jul 31, 2026 | mda_quarterly | Corteva is executing a strategic separation into two independent, publicly traded companies focused on its Seed and Crop Protection businesses. To support this transition, management initiated the 2026 Restructuring Actions, primarily involving workforce reductions, which are expected to yield $115 million to $125 million in annual run-rate savings by 2027. Additionally, the company is optimizing its Crop Protection manufacturing footprint, including the planned cessation of production in Asturias, Spain. Financial performance for the first half of 2026 showed resilience, with net sales rising 4% to $11.28 billion, driven by favorable currency impacts and growth in Seed pricing and mix. Operating EBITDA for the six-month period increased to $3.70 billion, benefiting from productivity gains and reduced royalty expenses, despite higher R&D and administrative costs. However, the second quarter saw a 1% decline in net sales due to volume shifts in North America and Brazil, alongside dry weather impacts in EMEA. Liquidity remains a priority, with the company utilizing short-term borrowings to fund working capital, the Bayer resolution payment, and the FMC rimisoxafen prepayment. While operating cash flow was pressured by these significant outflows, Corteva maintains access to $6.1 billion in unused credit facilities to support ongoing operations and capital allocation. |
| May 6, 2026 | mda_quarterly | Corteva announced its intent to separate into two independent publicly traded companies focusing on Seed and Crop Protection. To support this transition, the company initiated 2026 Restructuring Actions involving workforce reductions, expecting $70 million to $80 million in pre-tax charges and run-rate savings of $115 million to $125 million by 2027. First-quarter 2026 net sales rose 11% to $4.905 billion, driven by a 6% volume increase and favorable currency impacts from the Euro and Brazilian Real. The Seed segment reported a 12% sales increase to $3.023 billion, supported by strong demand for top technology and volume gains in North America and EMEA. Crop Protection sales grew 10% to $1.882 billion, fueled by demand for spinosyns and new products, though competitive dynamics in Latin America and Asia Pacific led to a 2% price decline. Operating EBITDA increased to $1.438 billion. Liquidity remains stable with $1.966 billion in cash and marketable securities, although operating cash flow was negative $2.885 billion, primarily due to a Bayer resolution payment. Additionally, the Board approved a $1.5 billion contribution to the principal U.S. pension plan to be made by July 31, 2026. |
Source: SEC EDGAR filing text and events; period Aug 14, 2026; filed Aug 14, 2026.
CTVA company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.